Process for the preparation of a sulfonamide structured kinase inhibitor
The present disclosure relates to an improved process for the preparation of a sulfonamide structured kinase inhibitor, namely N-(2′,4′-difluoro-5-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)-[1,1′-biphenyl]-3-yl)cyclopropanesulfonamide (1A) and pharmaceutically acceptable salts thereof. Compound of formula (1A) is a selective inhibitor of FGFR/VEGFR kinase families and is useful in the treatment of cancer.
1. A compound chosen from:
2. A process for the preparation of a compound of formula (IV)
comprising the steps of:
a) reacting 2′,4′-difluoro-[1,1′-biphenyl]-3,5-diamine of formula (V)
with 4-bromo-2-fluoronitrobenzene in the presence of an organic base and an organosilane to obtain a compound of formula (IV)
b) treating the product obtained from step (a) with an organic acid and isolating the formed organic salt;
c) releasing the compound of formula (IV) from its salt form.
3. The process according to claim 2 , wherein the organic base used in step a) is N,N-diisopropylethylamine (DIPEA).
4. The process according to claim 2 , wherein the organosilane used in step a) is ethoxytrimethylsilane.
5. The process according to claim 2 , wherein the organic acid used in step b) is a sulfonic acid.
6. The process according to claim 5 , wherein the sulfonic acid is methanesulfonic acid, p-toluenesulfonic acid, o-toluenesulfonic acid, ethanesulfonic acid or benzenesulfonic acid.
7. The process according to claim 6 , wherein the sulfonic acid is methanesulfonic acid or p-toluenesulfonic acid.
8. The process according to claim 7 , wherein the sulfonic acid is methanesulfonic acid.
9. The process according to claim 2 , wherein step c) is carried out by heating the salt in an organic solvent in the presence of an organic base.